Most Read Articles
31 May 2016
Tacrolimus is safe and effective in inducing and maintaining remission in paediatric patients with biologic refractory inflammatory bowel disease (IBD), according to a study presented at the 49th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition in Athens, Greece.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

Rachel Soon, 25 Jul 2018

MIMS Pharmacist presents an overview of Lactobacillus plantarum 299v's physiological role, as well as contemporary research on its pharmacology and effects.

01 Mar 2018
Lifetime prevalence of acute pain leading to the use of analgesics approaches 100% in the general population, and pharmacists are a pivotal first point of contact for patients in their journey to better pain management. Noting the need for pharmacists to be more aware of their evolving role as a community pharmacist, GlaxoSmithKline Consumer Healthcare partnered with MIMS Education to organize a workshop that served as a platform for robust knowledge-sharing. Below are highlights from the workshop.

Prereactivation propranolol reduces PTSD symptoms

14 May 2018
Mind training is the key to prevent PTSD among emergency responders handling trauma cases

Prereactivation propranolol, a treatment protocol suggested by reconsolidation theory, shows potential in reducing symptoms of post-traumatic stress disorder (PTSD), a recent study has shown.

There was a statistically significant 11.50 estimated group difference in post-treatment Clinician-Administered PTSD Scale (CAPS) score, adjusted for pretreatment values (analysis of covariance). The within-group pre- to post-treatment effect sizes (Cohen’s d) were 1.76 and 1.25 for propranolol and placebo, respectively.

The mixed linear model’s estimated time-by-group interaction for the patient-rated PTSD Checklist–Specific (PCL-S) generated an average decrease of 2.43 points per week. The total significant difference was 14.58 points above that of placebo. The pre- to post-treatment effect sizes were 2.74 and 0.55 for propranolol and placebo, respectively.

Analyses per protocol revealed similar significant results for both outcomes.

A total of 60 adults diagnosed with long-standing PTSD were included in this 6-week, double-blind, placebo-controlled, randomized clinical trial. The investigators administered propranolol or placebo 90 minutes before a brief memory reactivation session, once a week for 6 consecutive weeks.

They hypothesized a significant treatment effect of trauma reactivation with propranolol vs trauma reactivation with placebo in reducing PTSD symptoms on both the CAPS and PCL-S in an intention-to-treat analysis.

“Replication studies using a long-term follow-up in various trauma populations are required,” the investigators said.

A noradrenergic beta-receptor, propranolol has been used in this study as a putative reconsolidation blocker to reduce PTSD symptoms, they noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
31 May 2016
Tacrolimus is safe and effective in inducing and maintaining remission in paediatric patients with biologic refractory inflammatory bowel disease (IBD), according to a study presented at the 49th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition in Athens, Greece.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

Rachel Soon, 25 Jul 2018

MIMS Pharmacist presents an overview of Lactobacillus plantarum 299v's physiological role, as well as contemporary research on its pharmacology and effects.

01 Mar 2018
Lifetime prevalence of acute pain leading to the use of analgesics approaches 100% in the general population, and pharmacists are a pivotal first point of contact for patients in their journey to better pain management. Noting the need for pharmacists to be more aware of their evolving role as a community pharmacist, GlaxoSmithKline Consumer Healthcare partnered with MIMS Education to organize a workshop that served as a platform for robust knowledge-sharing. Below are highlights from the workshop.